Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)
Status:
Terminated
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to evaluate the superiority of treatment with PegIntron and
Rebetol over no antiviral therapy (control group) in subjects with chronic hepatitis C and
type C compensated cirrhosis. Subjects will be randomized in a ratio of 2:1 (Treatment Arm to
Control Arm). Subjects in the Treatment Arm will receive combination therapy with PegIntron
and Rebetol for 48 weeks; then will enter a 24-week post-treatment Follow-up. Subjects who
have detectable Hepatitis C Virus-RNA at Treatment Week 24 will discontinue treatment and
enter Follow-up.